论文部分内容阅读
[目的]比较吉西他滨联合顺铂或奥沙利铂治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。[方法]87例晚期NSCLC患者分为两组:顺铂组42例,吉西他滨1000mg/m2,d1,d8;顺铂25mg/m2,d1～d3。奥沙利铂组45例,吉西他滨1000mg/m2,d1,d8;奥沙利铂130mg/m2,d1。28d/周期。评价有效率、疾病进展时间和毒副反应。[结果]顺铂组与奥沙利铂组的有效率分别为28.6%和31.1%(P=0.8),中位疾病进展时间分别为6.2个月(4.0~8.5个月)和5.7个月(4.5~7.8个月)(P=0.07)。两组主要毒副反应为胃肠道反应、周围神经毒性及骨髓毒性。顺铂组胃肠道反应的发生率(81.0%)明显高于奥沙利铂组(51.1%)(χ2=8.6,P=0.0)。奥沙利铂组的周围神经毒性的发生率(57.8%)明显高于顺铂组4.8%(χ2=28.0,P=0.0)。[结论]吉西他滨联合顺铂或奥沙利铂是晚期NSCLC的有效方案,均可作为晚期NSCLC的一线治疗方案。
[Objective] To compare the efficacy and toxicity of gemcitabine combined with cisplatin or oxaliplatin in the treatment of advanced non-small cell lung cancer (NSCLC). [Method] Eighty-seven patients with advanced NSCLC were divided into two groups: cisplatin group (n = 42), gemcitabine (1000mg / m2), d1 and d8, cisplatin 25mg / m2 and d1 ~ d3. Oxaliplatin group 45 cases, gemcitabine 1000mg / m2, d1, d8; oxaliplatin 130mg / m2, d1.28d / cycle. Evaluation of efficiency, disease progression time and side effects. [Results] The effective rates of cisplatin and oxaliplatin were 28.6% and 31.1% respectively (P = 0.8), and the median progression time was 6.2 months (4.0-8.5 months) and 5.7 months 4.5 to 7.8 months) (P = 0.07). The two main toxicities were gastrointestinal reactions, peripheral neurotoxicity and myelotoxicity. The incidence of gastrointestinal reactions (81.0%) in cisplatin group was significantly higher than that in oxaliplatin group (51.1%) (χ2 = 8.6, P = 0.0). The incidence of peripheral neurotoxicity in oxaliplatin group (57.8%) was significantly higher than that in cisplatin group (χ2 = 28.0, P = 0.0). [Conclusion] Gemcitabine combined with cisplatin or oxaliplatin is an effective regimen for advanced NSCLC, both of which can be used as the first-line treatment for advanced NSCLC.